3rd Annual Pharmaceutical Regulatory Affairs Summit

The latest tendencies of instability in the pharmaceutical sector affected all the companies in the industry. Current challenges open new perspectives for the pharma players. And results of these actions depend on market knowledge, understanding of trends and ability to react in time. What is the future of the regulatory affairs field? Do you know the potential changes in the pharma regulations? Make sure that you are ready for them. Join us at our conference for the top senior-level decision-makers to find the answers and fresh perspectives of the leading experts in the field.

The 3rd Annual Pharmaceutical Regulatory Affairs Summit has been designed to cover all the current hot topics and challenges regarding Regulatory Affairs to explore new case studies based on top regulatory leaders’ experience. This interactive business conference will provide you with more valuable knowledge about innovative medicine in regulatory systems, intellectual property rights and actual policymaker’s challenges, the role of price regulation in the quality of new pharmaceuticals, a perspective of data protection in RA strategy, the potential of artificial intelligence on the regulatory affairs systems, using blockchain technology in RA and many others.

At our highly interactive event, you will hear from leading pharmaceutical companies internationally that have managed to succeed in their RA operations. You will also benefit from remarkable networking opportunities due to the limited seats at this business event. It will be the right place for sharing ideas, getting insights and inspiration, learning from experienced colleagues and establishing important business contacts!

Join us and register today

Stay on top of the latest trends

Key speakers

Caroline Petit

Caroline Petit

International Advertising and Promotions Lead, Associate Director, Global Regulatory Affairs
Elvira Falco

Elvira Falco

Licence to Operate Head (SPAIN)
Luana Riccardi

Luana Riccardi

Regulatory Strategy Associate Director
Mónica Perea Vélez

Mónica Perea Vélez

CMC Advocacy and Policy Director
Iivi Ammon

Iivi Ammon

Head of Regulatory Affairs, Baltic countries

Key topics

  • Overview of the legislative and non-legislative actions within the new EU pharmaceutical strategy
  • A balance between affordable access to medicines and preserving incentives for innovation
  • Advantages of blockchain technology implementation in your RA strategy
  • AI technology as a way to analyse patterns in data sets to help understand the implications, benefits and success rates of new drugs before launching them
  • Big data analytics: High-performance systems to analyse the volumes of data generated during the drug discovery
  • EU novel strategies for safe and affordable medicines
  • What are the general obligations of the clinical trials regulation with regard to personal data?
  • Blockchain technology as a tool to stop the usage of counterfeit medicines and substandard drugs

Who Should Attend

Members of board, C-level, Senior/Global Vice Presidents, Directors, Heads of departments from the pharmaceutical industry involved in:

  • Regulatory Affairs
  • Regulatory Intelligence
  • Regulatory Policy
  • Regulatory Compliance
  • Regulatory Operations
  • Regulatory Project Management
  • Regulatory Information Management
  • Regulatory Devices
  • Regulatory Strategy
  • Regulatory Submission
  • Regulatory Sciences
  • Regulatory Documentation
  • Regulatory Labelling
  • Regulatory Development
  • Data Collection
  • Data Management
  • Lifecycle Management
  • Regulatory Writing
  • Scientific Affairs